Home Biosimilar Antibodies Immunology & Inflammation IL Receptor Imsidolimab (Anti-IL-1RL2 / IL-36R)
For research use only. Not for use in humans.

Imsidolimab (Anti-IL-1RL2 / IL-36R)

Synonyms: ANB 019

Imsidolimab (Anti-IL-1RL2 / IL-36R) is a high-affinity, humanized monoclonal antibody targeting IL-36R. It has potential application in generalized pustular psoriasis (GPP) and other inflammatory skin diseases. MW :150 KD.

Imsidolimab (Anti-IL-1RL2 / IL-36R)

Quality Control

Batch: A266701 Purity: 99% Protein concentration: 13.5mg/ml Endotoxin Level: ＜1EU/mg
99

Specificity

Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Imsidolimab (Anti-IL-1RL2 / IL-36R) is a high-affinity, humanized monoclonal antibody targeting IL-36R. It has potential application in generalized pustular psoriasis (GPP) and other inflammatory skin diseases. MW :150 KD.
References

Product Details

CAS No. 2102543-86-0
Molecular Weight 150
Isotype Human IgG4SP
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT07449156 NOT_YET_RECRUITING Drug: HB0043|Drug: Placebo Acne Vulgaris Shanghai Huaota Biopharmaceutical Co., Ltd. 2026-03-27 PHASE1; PHASE2
NCT06895499 RECRUITING Drug: HB0043|Drug: HB0043|Drug: HB0043 Hidradenitis Suppurativa Shanghai Huaota Biopharmaceutical Co., Ltd. 2025-03-19 PHASE1; PHASE2
NCT06092216 TERMINATED Drug: Spesolimab Pyoderma Gangrenosum Icahn School of Medicine at Mount Sinai 2023-09-23 PHASE2
NCT05366855 TERMINATED Drug: Double-blind 200 mg imsidolimab|Drug: Open-label 200 m Generalized Pustular Psoriasis Vanda Pharmaceuticals 2022-04-21 PHASE3
NCT05352893 COMPLETED Drug: 750 mg Imsidolimab|Drug: 300 mg Imsidolimab Generalized Pustular Psoriasis Vanda Pharmaceuticals 2022-04-14 PHASE3
NCT05460455 COMPLETED Drug: Recombinant Humanized Anti-IL-36R Monoclonal antibody Healthy Shanghai Huaota Biopharmaceutical Co., Ltd. 2022-10-13 PHASE1

(data from https://clinicaltrials.gov, updated on 2026-03-04)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.